[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fertility-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fertility-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,41,67,104,126,148,166,190,215,239,265,292,321,345,373],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100299658","male-fertility-preservation-using-cryopreservation-of-testicular-tissue-before-highly-gonadotoxic-cancer-treatment-100299658",false,"NCT03180918","Male Fertility Preservation Using Cryopreservation of Testicular Tissue Before Highly Gonadotoxic Cancer Treatment","Inclusion Criteria:\n\n* Prepubertal patients aged 3 months and older\n* Peri and pubertal patients after failure of sperm cryopreservation\n* Patients presenting high risk of infertility because of gonadotoxic treatments (i.e high dose of alkylating agents, testicular irradiation, total body irradiation).\n* Multidisciplinary team consensus in favour of proposition to cryopreserve testicular tissue\n\nExclusion Criteria:\n\n* Patients under the age of 3 months\n* Refusal of the patient and\u002For his parents\n* Treatments that are not highly gonadotoxic","MALE","3 Months","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","Background:\n\nDue to the remarkable improvement in treatments these last decades, long term survival can be expected in more than 80% of childhood cancer patients. Unfortunately, cancer treatments can be harmful to the gonads and can affect reproductive and endocrine functions. While loss of fertility is a major concern for most patients, sperm cryopreservation should be offered to all pubertal male patients. For prepubertal boys, only the experimental option of testicular biopsy in order to cryopreserve testicular stem cells can be proposed.\n\nPrimary aims\n\n\\- To cryopreserve testicular tissue of prepubertal patient receiving highly gonadotoxic oncological treatment.\n\nSecondary aims\n\n* To cryopreserve testicular tissue after failure of sperm cryopreservation in pubertal patient with high risk of infertility\n* To create a database in order to record clinical and biological follow-up data\n* To create a research biobank for future research projects\n\nMulticentric study: HUG, CHUV, UKBB",[26,27],"Childhood Cancer","Fertility Disorders","RECRUITING","2026-05-21",{"date":31,"type":32},"2026-05-27","ACTUAL",{"date":34,"type":32},"2015-01",{"date":36,"type":20},"2100-01",{"name":38,"class":39},"Gumy-Pause Fabienne","OTHER",3,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100525474","effect-of-a-probiotic-on-the-female-genital-tract-microbiota-of-participants-with-fertility-disorders-100525474","NCT06122207","Effect of a Probiotic on the Female Genital Tract Microbiota of Participants With Fertility Disorders.","A Randomized, Double-blind, Placebo-controlled Study to Confirm the Positive Effect of Fertibiome® (Ligilactobacillus Salivarius PS11610) on the Female Genital Tract Microbiota of Couples or Women With Fertility Disorders.","PROFEC II","Inclusion Criteria:\n\n* Couples or women with ages between 18 and 45 for woman and between 18 and 55 for man (in case of couple participation).\n* Couples or women with fertility disorders.\n* Couples or women undergoing IVF treatment or willing to start it.\n* Signature of the Informed Consent.\n\nExclusion Criteria:\n\n* Women, not participating in the study with a couple, who have not undergone at least 4 cycles of artificial insemination with donor's sperm (AID) or 1 cycle of IVF without achieving evolutionary pregnancy.\n* Women with Body Mass Index (BMI) ≥ 30.\n* Couples where the woman has not infertility diagnosis while the man has any of the following characteristics:\n\n  * Azoospermia\n  * Sperm motility (A + B) \\\u003C 25%.\n  * Sperm morphology ≤ 2%.\n  * Vas deferens obstruction.\n* Couples or women with any of the following characteristics:\n\n  * Chronic diseases that cause intestinal malabsortion.\n  * Congenital or acquired immunodeficiency.\n  * Current history or diagnosis of alcohol, tobacco, or drug abuse.\n  * Uncertainty about the willingness or ability of participants to comply with the requirements of the protocol.\n  * Under treatment with probiotics during the last week.","ALL","45 Years",{"count":52,"type":20},120,[23],"In the last decades, numerous publications have broken the old paradigm that considered the urogenital tracts as sterile, demonstrating that microorganisms present in the urogenital tract represent the 9% of the whole human microbiome. Healthy urogenital microbiome improves implantation rate and pregnancy outcomes, whereas 40% of dysbiosis prevalence is observed in women under assisted reproductive treatment (ART).\n\nInfertility causes are associated with male, female, or combined failure. It has been shown that oral probiotic treatment, mainly with Lactobacillus, recovers a healthy vaginal microbiota without safety concerns.\n\nAn interventional, randomized, double-blind, placebo-controlled study will be conducted to confirm the positive effect of the commercial probiotic product Fertibiome® on the vaginal dysbiosis of couples or women with fertility disorders.\n\nThe duration of the study will be of 6 months approximately, including 6 months of product intake. In case of pregnancy during intervention, women will continue their participation until week 12 of gestation.\n\nParticipants will be randomly assigned to one of the two study groups: control group with placebo administration or probiotic administration group. Women will take 1 capsule every 12 hours and men 1 per day. In case of women participating alone they will take 1 capsule every 12 hours. In case of pregnancy, only women will continue taking 1 capsule per day for the first 12 weeks.",[27],"2026-04-07",{"date":58,"type":32},"2026-04-13",{"date":60,"type":32},"2024-02-14",{"date":62,"type":20},"2027-03",{"name":64,"class":65},"ProbiSearch SL","INDUSTRY",2,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":75,"minAge":4,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":40},"100410056","biomarkers-of-endometrial-receptivity-100410056","NCT04619524","Biomarkers of Endometrial Receptivity","Biomarkers of Endometrial Receptivity: A Prospective Multicenter Study on Proteomic Biomarkers of Endometrial Receptivity in Cervical Mucus ( PRO BIOMER - CM )","BIOMER","Inclusion Criteria - Arm A - stimulated cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* follicle stimulating hormone (FSH) \\\u003C 10 IU\u002FL on the third day\n* basal antral follicle count of 5-15\n* undergoing the same routine gonadotrophin-releasing hormone agonist (GnRHa) long depot or gonadotrophin-releasing hormone antagonist (GnRH-ant.) protocol\n* informed consent\n\nExclusion Criteria - Arm A - stimulated cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria)\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 1.0 mIU\u002Fml or more than 20 oocytes, milli-International unit (mIU)\n* previous ovarian hyperstimulation syndrome (OHSS)\n* presence of any structural abnormality of the reproductive system\n* donor oocyte cycles\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL\n* low response to stimulation\n* endometrium \\\u003C 8 mm at the day of human chorionic gonadotropin (hCG) or ET\n* number of retrieved oocytes 5 - 20\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* OHSS\n* IVF cycle cancelled before ET\n* other than easy one high-quality blastocyst transfer (at least grade 3BB)\n\nInclusion criteria - Arm B - substituted cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder at stimulation\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* FSH \\\u003C 10 IU\u002FL on the third day\n* undergoing the same routine estrogen\u002Fprogesterone substituted cycle\n* informed consent\n\nExclusion criteria - Arm B - substituted cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders such as diabetes, metabolic syndrome, and thyroid disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria), hyperprolactinaemia\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 0.5 mIU\u002Fml in the stimulated cycle\n* previous OHSS\n* presence of any structural abnormality of the reproductive system\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL in the stimulated cycle\n* number of retrieved oocytes 5 - 20 in the stimulated cycle\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* endometrium less than 8 mm at the day of thawing and transfer indication\n* thawed blastocyst cycle cancelled before ET\n* other than easy one best quality frozen\u002Fthawed blastocyst transfer (at least grade 3BB)","FEMALE","36 Years",{"count":78,"type":20},476,[23],"Analysis of proteins from cervical mucus will be done in patients undergoing infertility treatment (fresh or frozen embryo transfer). Cervical mucus will be analysed for potential new biomarkers of endometrium receptivity. Comparison of the peptide spectrum will be done for the pregnant and not pregnant patients.",[82,83,27,84],"IVF","Infertility Treatment","Embryo Transfer",[86,87,88,89,90,91,92,93,94],"cervix","mucus","endometrium","receptivity","biomarker","proteomics","infertility","in-vitro","fertilisation","2026-03-19",{"date":97,"type":32},"2026-03-20",{"date":99,"type":32},"2018-05-01",{"date":101,"type":20},"2026-12-31",{"name":103,"class":39},"The Institute of Molecular and Translational Medicine, Czech Republic",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":15,"minAge":111,"maxAge":17,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100520975","cryopreservation-of-prepubertal-testicular-tissue-for-preservation-of-fertility-in-young-boys-with-cancer-100520975","NCT06063551","Cryopreservation of Prepubertal Testicular Tissue for Preservation of Fertility in Young Boys With Cancer","Cryopreservation of Prepubertal Testicular Tissue for Preservation","Inclusion Criteria:\n\n* Pre- and peripubertal boys\n* Due to receive cancer treatment that is predicted to have a high risk (\\>80%) of infertility\n* Consent to removal of testicular tissue for storage and research\n* Unable to produce a semen sample by masturbation\n\nExclusion Criteria:\n\n* Participation in study would delay treatment\n* Too unwell to undergo the procedure\n* Pre-existing testicular pathology\u002Fprevious testicular surgery (eg orchidopexy)\n* Able to produce a semen sample for cryopreservation","1 Day",{"count":19,"type":20},[23],"Prepubertal boys treated for cancer are at risk of infertility as a result of their treatment. At present there are no options to preserve fertility in these boys. With informed consent, the investigators aim to cryopreserve (freeze) testis tissue biopsies taken from boys undergoing cancer therapy with a high risk of infertility. A portion of cryopreserved tissue will be securely stored, which in the future may be used to restore fertility in the patients. A second portion of the tissue will be used for laboratory work aimed at understanding the conditions required for development of the germ cells.\n\nPatients will be recruited from the Oncology Department at the Royal Hospital for Children and Young People (RHCYP) in Edinburgh. Tissue will be obtained from prepubertal patients with cancer who are about to undergo treatment with a high risk (\\>80%) of infertility. Informed consent will be obtained from the patients legal guardian (and patient if applicable) for the procedure and subsequent use of tissue. A testis biopsy from one testis will be performed and if possible will coincide with a planned routine procedure requiring general anaesthetic in order to avoid the need for additional anaesthesia.\n\nThe procedure will take place at RHCYP during the initial assessment and prior to the commencement of cancer treatment and will not result in delay of treatment. Tissue will be assessed for the presence of sperm for storage using existing methods. In addition, tissue will be cryopreserved by Tissue and Cells Directorate, SNBTS in Edinburgh. The tissue will be stored for up to 55 years in accordance with current legislation (HFEA Act as amended 2005). Research will be carried out at the MRC Centre for Reproductive Health in accordance with Human Tissue (Scotland) Act 2006.",[27,26],"2025-11-19",{"date":118,"type":32},"2025-11-20",{"date":120,"type":32},"2016-04-01",{"date":122,"type":20},"2061-04",{"name":124,"class":39},"University of Edinburgh",1,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":133,"sex":75,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":111,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":125},"100587434","data-collection-protocol-for-the-development-of-chloe-oq-an-ai-model-for-assessing-oocytes-quality-100587434","NCT06928337","Data Collection Protocol for the Development of CHLOE-OQ, an AI Model for Assessing Oocytes Quality.","CHLOE Oocyte Data Collection Protocol","Inclusion Criteria:\n\n* Women at least 18 years of age.\n* Embryos or eggs cultured in a time-lapse incubator connected to CHLOE Embryo Viewer.\n\nExclusion Criteria:\n\n* Women with autologous eggs",true,{"count":135,"type":20},350,"OBSERVATIONAL","This data collection protocol is aimed to allow the reliable and robust development (training, verification, and validations) of CHLOE technology-based applications as well as improve the machine learning stage of released devices\u002Fapplications. Additionally, a simulated use assessments will be conducted to ensure the correct and easy use of the CHLOE applications.",[27],"2025-08-06",{"date":141,"type":32},"2025-08-07",{"date":143,"type":32},"2025-05-01",{"date":145,"type":20},"2026-05-01",{"name":147,"class":65},"Fairtility",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":133,"sex":75,"minAge":17,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":125},"100594325","data-collection-and-professional-simulated-use-study-to-develop-an-embryo-quality-artificial-intelligence-ai-model-100594325","NCT07017972","Data Collection and Professional Simulated Use Study to Develop an Embryo Quality Artificial Intelligence (AI) Model","Multicenter Data Collection and Simulated-Use Assessment for CHLOE","Inclusion Criteria:\n\n1. Images and data of eggs or embryos available from egg retrievals by women undergoing standard egg-freezing or In vitro fertilization (IVF) treatments, using their own eggs or donor eggs.\n2. Women at least 18 years of age.\n3. Embryos or eggs cultured in a time-lapse incubator connected to the AI Embryo Viewer.\n\nExclusion Criteria:\n\n* Women with no available own or donor eggs.",{"count":156,"type":20},4000,"This protocol supports the reliable development and improvement of Artificial Intelligence (AI)-based applications by enabling training, verification, and validation using high-quality real clinical data. It also aims to enhance machine learning in developmental-use AI software.\n\nIn addition, the professional user simulated use will ensure correct and easy use of the AI applications.",[27],"2025-08-04",{"date":141,"type":32},{"date":162,"type":32},"2025-06-20",{"date":164,"type":20},"2027-06-20",{"name":147,"class":65},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":75,"minAge":17,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":66},"100592781","phase-2-menopur-and-rekovelle-combination-study-version-20-100592781","NCT06997900","Menopur And Rekovelle Combination Study Version 2.0","MARCS 2","Inclusion Criteria:\n\n* Women aged 18 to 40 years inclusively at the time of consent form signature\n* Diagnosis of unexplained infertility, tubal infertility, endometriosis stage I\u002FII or male factor infertility\n* Regular menstrual cycles of 24-35 days\n* Presence of both ovaries\n* Early follicular phase FSH serum concentration \\\u003C10 IU\u002FL measured between Day 2 and Day 5 of menstrual cycle within the previous 24 months\n* First IVF\u002FICSI cycle\n* IVF antagonist protocol prescribed\n* Partner or donor ejaculated sperm (fresh or frozen) used for fertilization\n\nExclusion Criteria:\n\n* Women undergoing oocyte donation\n* Endometriosis stage III\u002FIV\n* High risk of OHSS (AMH ≥ 35 pmol\u002FL)\n* Body Mass Index (BMI) \\> 40 kg\u002Fm2 Protocol number: IIS-1056 MARCS 2.0 Study Version: 1.1 - Date : 14 APR 2025 Page 12 of 28\n* Gynaecological haemorrhages of unknown aetiology\n* History of recurrent miscarriages defined as ≥ 3 consecutive losses\n* Renal or hepatic impairment\n* Hypersensitivity to any active ingredient or excipients in follitropin delta and\u002For HP-hMG\n* Tumours of hypothalamus or pituitary gland\n* Ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome\n* Current or history of ovarian, uterine or mammary carcinoma\n* History of thrombophilia\n* Use of hormonal preparations (except for 17β-estradiol, testosterone gel, DHEA and thyroid medication) during the last menstrual cycle\n* Women participating in any other interventional research project","40 Years",{"count":175,"type":20},200,[177],"PHASE2","The goal of this clinical trial is to evaluate the safety and effectiveness of a personalized ovarian stimulation regimen in women aged 18 to 40 undergoing in vitro fertilization (IVF). The main question it aims to answer is:\n\n\\- Does personalizing the starting doses of follitropin delta (REKOVELLE) and HP-hMG (MENOPUR) based on both age and body lead to similar results as anti-Müllerian hormone (AMH) and weight based dosing ?\n\nResearchers will compare the new dosing regimen to the MARCS study results to see if this new approach leads to similar outcomes\n\nParticipants will:\n\n* Receive ovarian stimulation using a personalized dose of REKOVELLE aND MENOPUR based on age and weight\n* Be monitored through ultrasound imaging and blood tests to measure estradiol (E2) levels\n* Undergo standard IVF procedures including egg retrieval and embryo assessment",[82,180,27],"Controlled Ovarian Simulation","2025-07-29",{"date":183,"type":32},"2025-07-31",{"date":185,"type":32},"2025-07-04",{"date":187,"type":20},"2027-08",{"name":189,"class":65},"Clinique Ovo",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":75,"minAge":17,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":125},"100501284","medically-assisted-fertilization-techniques-in-systemic-immunoreumatologic-diseases-100501284","NCT05807256","Medically Assisted Fertilization Techniques in Systemic Immunoreumatologic Diseases","Assessment of Maternal-fetal Outcome in Pregnancy From Medically Assisted Fertilization Techniques in Women With Systemic Immunoreumatologic Diseases","Inclusion Criteria:\n\n* Patients diagnosed with systemic immunoreumatologic disease such as SLE, APS, RA, SpA, SclS, SS, PM-DM, vasculitis\n* patients who have performed one or more PMAs between January 2000 and April 2021\n* patients who had their last follow-up by February 2022\n\nExclusion Criteria:\n\n* Patients diagnosed with only one organ autoimmunity (e.g., diabetes mellitus I, thyroiditis of Hashimoto's, celiac disease or chronic inflammatory bowel disease in the absence of systemic disease associated);\n* patients with severe renal failure, significant pulmonary hypertension or cardiomyopathy severe.","50 Years",{"count":199,"type":20},500,"Systemic rheumatological diseases often occur in young women of childbearing age and can therefore impact fertility. There are diseases, such as arthritis, which present no contraindication to assisted reproductive techniques (ARTs), because there is no influence on the disease itself if the disease activity at conception is stable. On the other hand, patients suffering from connective tissue diseases, primarily Systemic Lupus Erythematosus (SLE) and patients suffering from primary or SLE-related Anti-Phospholipid Antibody Syndrome (APS), deserve more targeted therapies both in the context of ARTs and in the ensuing pregnancy.\n\nTo evaluate the response to ARTs in patients with systemic rheumatological diseases, both in terms of reactivation of the underlying pathology and in terms of ARTs outcome.",[202,27,203,204,205],"Rheumatic Diseases","Pregnancy, High Risk","Pregnancy Complications","Immunologic Disease","2025-06-17",{"date":208,"type":32},"2025-06-18",{"date":210,"type":32},"2022-05-04",{"date":212,"type":20},"2025-11-30",{"name":214,"class":39},"IRCCS San Raffaele",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":133,"sex":75,"minAge":17,"maxAge":173,"enrollmentInfo":223,"targetDuration":4,"studyType":21,"phases":224,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":237,"locationsCount":125},"100531082","phase-4-trap-study-testosterone-for-androgen-receptor-polymorphism-100531082","NCT06195163","TRAP Study: Testosterone for Androgen Receptor Polymorphism","Transdermal Testosterone Pretreatment in Poor Responders With Androgen Receptor Polymorphism Undergoing ICSI: A Randomized Clinical Investigation.","TRAP","Inclusion Criteria:\n\n* Patients with low ovarian reserve according to Bologna criteria: at least two of the following three:\n\n  1. Age equal to or greater than 40 years.\n  2. Previous cycle with less than 4 oocytes retrieved.\n  3. Low ovarian reserve markers (antral follicle count \\\u003C5-7; AMH \\\u003C0.5-1.1 ng).\n* Carriers of androgen receptor polymorphism: between 22 and 24 CAG repeats.\n* Body Mass Index (BMI) less than 32.\n* Indication for in vitro fertilization.\n* Presence of both ovaries.\n* Absence of ovarian cysts.\n* Absence of endometriosis.\n* Normal karyotype and fragile X study.\n* Absence of severe male factor.\n* Semen sample from ejaculate.\n* Ability to comply with the study protocol.\n* To have given written consent.\n\nExclusion Criteria:\n\n* Non-compliance with instructions or non-formalization of informed consent.\n* Concurrent participation in another study.",{"count":19,"type":20},[225],"PHASE4","To determine whether pretreatment with transdermal testosterone increases the number of cumulus-oocyte complexes (COCs) obtained after ovarian stimulation by more than 1.5 in patients with low ovarian reserve and androgen receptor polymorphism undergoing intracytoplasmic sperm injection (ICSI).",[27],[229],"ovarian stimulation; testosterone","NOT_YET_RECRUITING","2025-05-06",{"date":233,"type":32},"2025-05-09",{"date":235,"type":20},"2025-09-30",{"date":101,"type":20},{"name":238,"class":39},"Instituto Bernabeu",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":75,"minAge":17,"maxAge":50,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":263,"locationsCount":66},"100577531","the-effect-of-mindfulness-based-lifestyle-support-program-on-infertile-women-100577531","NCT06799507","The Effect of Mindfulness-Based Lifestyle Support Program on Infertile Women","The Effect of Mindfulness-Based Lifestyle Support Program on Quality of Life, Lifestyle, Mindfulness Level and Treatment Outcomes in Infertile Women","Inclusion Criteria:\n\n* Primary infertility,\n* Going to undergo IVF treatment,\n* Under 45 years of age,\n* Having a smart phone or computer\n\nExclusion Criteria:\n\n* Participate in any program related to mindfulness\n* Prior mindfulness training\n* Knowing\u002Fdoing mindfulness practices beforehand\n* Having any psychiatric disorder\n* Having any chronic disease\n* Disability (hearing\u002Fvision etc.)\n* Attending less than 80% of the trainings (missing more than 2 Mindfulness trainings)\n* Conception during research",{"count":247,"type":20},92,[23],"This randomized controlled trial aimed to determine whether a mindfulness-based lifestyle support program would improve quality of life, lifestyle, mindfulness, attention and meditation level and treatment outcomes in women undergoing IVF treatment.",[27,251],"Infertility (IVF Patients)",[253,254,255,256],"Infertility","Mindfulness","Quality of Life","Life Style","2025-01-31",{"date":259,"type":32},"2025-02-03",{"date":257,"type":32},{"date":262,"type":20},"2026-06-15",{"name":264,"class":39},"Dokuz Eylul University",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":133,"sex":49,"minAge":17,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":125},"100215456","reproductive-hormones-during-sustained-administration-of-kisspeptin-100215456","NCT02081924","Reproductive Hormones During Sustained Administration of Kisspeptin","The Physiological Changes in Reproductive Hormones During Sustained Administration of Kisspeptin in Humans.","KisspeptPump","Inclusion criteria:\n\n* Aged 18-60 years old\n* Ability to give informed consent\n* Secondary hypogonadism (or healthy participant)\n\nExclusion criteria:\n\n* anaemia\n* medical problems such as severe heart, kidney or liver disease\n* blood donation in the last three months or intention to donate blood within 3 months of the end of the study\n* needle phobia\n* Poor venous access\n* Active psychiatric illness\n* Severe allergies\n* Impaired ability to provide full consent to take part in the study\n* Current alcohol or illicit drug dependence\n* Current pregnancy or breast feeding\n* Plans to conceive within 3 months of starting the study (barrier contraception must be used during and for 3 months after the end of the study)\n* Arthritis or any impairment of hand coordination which would preclude using a hormone pump","60 Years",{"count":275,"type":20},76,[23],"We want to find out what happens to reproductive hormone levels; Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH), testosterone and oestradiol when kisspeptin is administered to people for a period of 8 days each month, using either placebo (saline) or kisspeptin in doses of 0.1, 0.3 or 1.0 nmol\u002Fkg\u002Fhour.",[27,279],"Hypothalamic Dysfunction",[253,281,282],"Kisspeptin","Reproductive hormones","2024-09-09",{"date":285,"type":32},"2024-09-19",{"date":287,"type":32},"2014-04-02",{"date":289,"type":20},"2027-11-30",{"name":291,"class":39},"Imperial College London",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":133,"sex":75,"minAge":17,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":21,"phases":302,"briefSummary":303,"conditions":304,"keywords":306,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":125},"100539467","comparison-of-two-ppos-models-for-pituitary-suppression-100539467","NCT06304220","Comparison of Two PPOS Models for Pituitary Suppression","Comparación de Dos Modelos de PPOS Para supresión Hipofisaria en Ciclos de estimulación ovárica, Desogestrel vs Medroxiprogesterona","Inclusion Criteria:\n\n* BMI of 18-29,9 kg\u002Fm2\n* Ultrasound count of antral follicles prior to COH ≥ 12 follicles\n* Meeting the criteria for inclusion in the egg donation program\n* Normal karyotype and no active sexually transmitted diseases\n* No use of combined hormonal contraceptives one month before COH\n\nExclusion Criteria:\n\n* Patients excluded from the egg donation program\n* Untreated sexually transmitted diseases, positive serology for HBV, HIV, HCV\n* Blood disorders, neurodegenerative\u002Fpsychiatric diseases, carriers of X-linked genetic diseases, oncological diseases, endometriosis.\n* Oligomenorrhea (\\\u003C1 menstrual cycle in 3 months)\n* Use of combined hormonal contraceptives before COH","34 Years",{"count":301,"type":20},210,[23],"The scarcity of evidence regarding the interchangeable use of different progestogens poses challenges, particularly in international egg donation and fertility preservation programs where standardizing protocols is crucial for achieving consistent efficacy, efficiency, and safety outcomes. Consequently, there's a pressing need for clinical studies to assess the effects of various progestogens on clinical outcomes in controlled ovarian hyperstimulation cycles. This study, a pioneering effort, aims to compare the effects of two progestogens on oocyte performance, safety, and efficiency in an egg donation program involving young, healthy, normo-responding patients.",[305,27],"Infertility, Female",[307,308,309,310,311],"Primed-progestin ovarian stimulation protocol","Quality of oocytes","Oocyte yield","Ovarian Sensitivty Index","Controlled ovarian hyperstimulation","2024-06-17",{"date":314,"type":32},"2024-06-18",{"date":316,"type":20},"2024-07",{"date":318,"type":20},"2024-12",{"name":320,"class":65},"NextFertility",{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":133,"sex":75,"minAge":328,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":21,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":125},"100496157","the-danish-turner-cryopreservation-study-100496157","NCT05740579","The Danish TURNER Cryopreservation Study","DANTE","Inclusion Criteria:\n\n* 45,X karyotype or other Turner variant karyotypes (45,X\u002F46,XX mosaicism, ring X mosaicism, isochromosome X)\n* Age 2-17 years old\n* Ability to participate in a physical examination including a cardiac examination.\n* Signed consent from both parents.\n\nExclusion Criteria:\n\n* Severe cardiac disease which inhibits safe surgery and pregnancy.\n* Karyotype with Y chromosome material\n* Mental retardation","2 Years","17 Years",{"count":19,"type":20},[23],"The goal of this clinical trial is to investigate if cryopreservation of ovarian tissue in girls with Turner syndrome can improve their fertility and lead to increased number of liveborn babies of Turner syndrome mothers. Women with Turner syndrome suffer from premature ovarian insufficiency which leads to infertility and lack of estrogen.\n\nThe main questions it aims to answer are:\n\n* Does the number of pregnancies and liveborn children increase after cryopreservation of ovarian tissue in turner syndrome?\n* Is the possible to predict when a girl with Turner syndrome reach menopause using monitoring of sex hormones?\n* Is it possible to identify any genes causing ovarian failure in Turner syndrome females?\n\nParticipants between 2-18 years old will be asked to participate in a laparoscopic surgery and removal of one ovary in order to cryopreserve the tissue until adulthood. The the cortical tissue will be autotransplanted in order to preserve fertility. The participant will during the study period be monitored using sex hormones.\n\nFurthermore, the investigators wish to investigate the ovarian tissue using RNA sequencing and DNA methylation analysis.\n\nNo comparison group is present.",[27,334,335],"Turner Syndrome","Premature Ovarian Failure","2024-05-23",{"date":338,"type":32},"2024-05-24",{"date":340,"type":32},"2023-01-01",{"date":342,"type":20},"2051-01-01",{"name":344,"class":39},"University of Aarhus",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":75,"minAge":17,"maxAge":173,"enrollmentInfo":353,"targetDuration":4,"studyType":21,"phases":355,"briefSummary":356,"conditions":357,"keywords":362,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":125},"100495002","phase-4-prednisolone-administration-in-patients-with-unexplained-recurrent-miscarriages-100495002","NCT05725512","Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages","Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages, PREMI Trial","PREMI","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* Unexplained recurrent pregnancy loss: defined as the loss of ≥2 pregnancies, without any known cause for RM (parental chromosomal abnormalities, uterine anomalies, acquired or hereditary thrombophilia, endocrine diseases (such as hypothyroidism or diabetes)).\n* The miscarriages include:\n\n  * all consecutive or non-consecutive pregnancy losses before the 24th week of gestation verified by ultrasonography or uterine curettage and histology\n  * non-visualized pregnancies (including biochemical pregnancy losses and\u002For resolved and treated pregnancies of unknown location), verified by positive urine or serum hCG Ectopic and molar pregnancies are not included\n* Age 18 - 39 years at randomization (likelihood of miscarriages due to chromosomal aberrations is higher when age \\> 39 years. Such miscarriages are unlikely to be pre-vented by prednisolone therapy)\n* Conception confirmed by urinary pregnancy test, with estimated gestational age ≤ 7weeks\n* Willing and able to give informed consent in English or Dutch (IC)\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Any of the following diagnosis for the recurrent miscarriages\n\n  * Antiphospholipid syndrome (lupus anticoagulant and\u002F or anticardiolipin anti-bodies and\u002For beta-2 glycoprotein \\[IgG or IgM)\n  * Congenital uterine abnormalities (as assessed by 2D or 3d ultrasound, hys-terosonography, hysterosalpingogram or hysteroscopy)\n  * Abnormal parental karyotype\n* Instable or exacerbation of auto-immune diseases such as diabetes, thyroid disease, inflammatory bowel diseases or SLE\n* Inability to conceive within 1 year of recruitment\n* Current treatment with systemic prednisolone or other immune suppressive medication (for any indication)\n* Previous enrolment in the PREMI trial\n* Enrolment in any other trial that studies the effectiveness of an intervention on RM\n* Contraindications to prednisolone use:\n\n  * Known allergy for prednisolone\n  * Acute bacterial infection or parasite infection\n  * Active COVID infection\n  * Systemic sclerosis\n  * Ulcus ventriculi or ulcus duodeni in medical history\n  * Obesity with BMI \\>40\n* Some drugs are known to interact with Prednisolone, and thus women on the following drugs are not eligible to take part in the PREMI trial:\n\n  * Enzyme inducers, such as carbamazepine, fenobarbital, fenytoïne and ri-fampicine\n  * CYP3A inhibitors, such as Cobicistat or Ritonavir\n  * Cyclosporine\n  * Digoxin\n  * Vaccination (with inactivated virus or bacteria) during prednisolone use is possibly less effective",{"count":354,"type":20},490,[225],"Recurrent miscarriages (RM) affects 3% of all fertile couples, but remains unexplained in most cases, limiting therapeutic options. Possibly the maternal immune system plays a role in recurrent miscarriage. Prednisolone suppresses the immune system and might enable development of normal pregnancy.\n\nIn this randomized controlled clinical trial the investigators will study the effect of prednisolone on the live birth rate in patients with RM. Secondary, the tolerability and safety for mother and child and the cost-effectiveness is investigated.\n\nIn the study one group of pregnant women with RM and gestational age \\\u003C7 weeks will receive prednisolone, the other group will receive a placebo. Total use of the medicine during this study is 8 weeks, further care during the study is routinely antenatal care. Subjects will be asked to fill in 4 short questionnaires and will have contact with a research nurse at different time points to gain information on the course of the pregnancy and possible side effects.\n\nResults of the study will be implemented in (inter) national guidelines, to effect everyday practice.",[358,359,360,361,27],"Recurrent Miscarriage","Recurrent Pregnancy Loss","Habitual Abortion","Miscarriage",[363,364,365],"Recurrent pregnancy loss","Recurrent miscarriage","prednisolone",{"date":338,"type":32},{"date":368,"type":32},"2024-01-29",{"date":370,"type":20},"2027-07-29",{"name":372,"class":39},"Leiden University Medical Center",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":133,"sex":49,"minAge":17,"maxAge":76,"enrollmentInfo":381,"targetDuration":4,"studyType":21,"phases":383,"briefSummary":384,"conditions":385,"keywords":386,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":125},"100527169","live-birth-rate-after-sperm-selection-using-zymt-multi-850l-device-for-intra-uterine-insemination-100527169","NCT06144268","Live Birth Rate After Sperm Selection Using ZyMōt Multi (850µL) Device for Intra Uterine Insemination","Evaluation of Live Birth Rate After Sperm Selection Using Microfluidic Technology (ZyMōt Multi (850µL) Sperm Separation Device) for Intra Uterine Insemination.","FERTINSEM","Inclusion Criteria:\n\n* Fresh autologous ejaculate\n* Female age: \\\u003C37 at start of the first insemination\n* 1st IUI ever here, maximum 3 consecutive IUIs during max 6 months\n* BMI \\\u003C35\n* All natural cycles, ovulation induction allowed\n* Presence of 1 or 2 follicles at the last ultrasound\n* Regular menses (26-35 days)\n* \\>1 million Total Progressive Motile Sperm Count (TPMC) after previous routine capacitation with DGC\n* Presence of at least 1 potent tube after Hyfosy\n\nExclusion Criteria:\n\n* Presence of intracavitary pathology at ultrasound\n* Evidence of advance endometriosis (Grade 3 and 4)",{"count":382,"type":20},240,[23],"This single centre interventional pilot randomized control study intends to compare two methods of sperm preparation for couples referred for Intra Uterine Insemination (IUI) procedure. Couples will be randomly allocated to one of the two sperm selection methods: Density Gradient Centrifugation (DGC, standard) or ZyMōt Multi (850µL) device (treatment) groups. The study will compare the live birth rate (number of live births per number of IUI procedures) between the treatment and standard groups.",[253,27],[387,388,389],"Intra Uterine Insemination","Live birth","Microfluidic sperm selection",{"date":391,"type":32},"2024-01-30",{"date":393,"type":32},"2024-01-10",{"date":395,"type":20},"2027-12",{"name":397,"class":39},"Universitair Ziekenhuis Brussel"]